blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3564674

EP3564674 - HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.07.2022
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  23.07.2021
FormerGrant of patent is intended
Status updated on  14.04.2021
FormerExamination is in progress
Status updated on  20.05.2020
FormerRequest for examination was made
Status updated on  20.03.2020
FormerThe application has been published
Status updated on  04.10.2019
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, Arizona 85755 / US
[2019/45]
Inventor(s)01 / KOSMEDER, Jerome
1910 E. Innovation Park Drive
Tucson, AZ 85755 / US
02 / LEFEVER, Mark
13549 N Barlassina Dr
Oro Valley, AZ 85755 / US
03 / JOHNSON, Donald
1004 W. Blue Crest Dr.
Tucson, AZ 85755 / US
04 / FARRELL, Michael
8662 Placita Del Cardo
Tucson, AZ 85704 / US
05 / ZHILINA, Zhanna
7286 W. Clear Canyon Drive
Tucson, AZ 85743 / US
06 / BIENIARZ, Christopher
2263 E. Quiet Canyon Drive
Tucson, AZ 85718 / US
 [2021/33]
Former [2021/24]01 / KOSMEDER, Jerry
1910 E. Innovation Park Drive
Tucson, AZ 85755 / US
02 / LEFEVER, Mark
13549 N Barlassina Dr
Oro Valley, AZ 85755 / US
03 / JOHNSON, Donald
1004 W. Blue Crest Dr.
Tucson, AZ 85755 / US
04 / FARRELL, Michael
8662 Placita Del Cardo
Tucson, AZ 85704 / US
05 / ZHILINA, Zhanna
7286 W. Clear Canyon Drive
Tucson, AZ 85743 / US
06 / BIENIARZ, Christopher
2263 E. Quiet Canyon Drive
Tucson, AZ 85718 / US
Former [2019/45]01 / KOSMEDER, Jerry
5530 N. Moccasin Trail
Tucson, AZ 85750 / US
02 / LEFEVER, Mark
13549 N Barlassina Dr
Oro Valley, AZ 85755 / US
03 / JOHNSON, Donald
1004 W. Blue Crest Dr.
Tucson, AZ 85755 / US
04 / FARRELL, Michael
8662 Placita Del Cardo
Tucson, AZ 85704 / US
05 / ZHILINA, Zhanna
7286 W. Clear Canyon Drive
Tucson, AZ 85743 / US
06 / BIENIARZ, Christopher
2263 E. Quiet Canyon Drive
Tucson, AZ 85718 / US
Representative(s)Forresters IP LLP
Skygarden
Erika-Mann-Straße 11
80636 München / DE
[2021/34]
Former [2019/45]Bond, Christopher William
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Application number, filing date19178774.601.11.2007
[2019/45]
Priority number, dateUS20060856133P01.11.2006         Original published format: US 856133 P
[2019/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3564674
Date:06.11.2019
Language:EN
[2019/45]
Type: B1 Patent specification 
No.:EP3564674
Date:25.08.2021
Language:EN
[2021/34]
Search report(s)(Supplementary) European search report - dispatched on:EP25.09.2019
ClassificationIPC:C07D271/12, G01N33/532, G01N33/58, A61P35/00, A61P37/04
[2021/15]
CPC:
C07D495/04 (EP,US); G01N33/5308 (US); A61P35/00 (EP);
A61P37/04 (EP); C07D215/52 (EP,US); C07D231/16 (EP,US);
C07D241/44 (EP,US); C07D243/12 (EP,US); C07D271/08 (EP,US);
C07D271/12 (EP,US); C07D277/48 (EP,US); C07D277/76 (EP,US);
C07D311/12 (EP,US); C07D417/12 (EP,US); C07D491/052 (EP,US);
C07D491/056 (EP,US); C07D491/147 (EP,US); C07D493/04 (EP,US);
C07D493/14 (EP,US); C07D498/04 (EP,US); C12Q1/6804 (US);
C12Q1/6841 (US); C12Q1/6886 (US); G01N33/532 (EP,US);
G01N33/533 (EP,US); G01N33/58 (EP,US); G01N33/582 (EP,US);
G01N33/583 (EP,US); Y10S435/961 (EP,US); Y10S530/807 (EP,US) (-)
Former IPC [2019/45]G01N33/532, G01N33/533, G01N33/58, C12Q1/68, C07D271/12, C07D495/04
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2020/17]
Former [2019/45]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:HAPTENE, HAPTENKONJUGATE, ZUSAMMENSETZUNGEN DARAUS UND VERFAHREN ZU DEREN HERSTELLUNG UND VERWENDUNG[2019/45]
English:HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE[2019/45]
French:HAPTÈNES, CONJUGUÉS DE HAPTÈNES, LEURS COMPOSITIONS ET LEUR PROCÉDÉ DE PRÉPARATION ET D'UTILISATION[2019/45]
Examination procedure16.03.2020Amendment by applicant (claims and/or description)
16.03.2020Examination requested  [2020/17]
16.03.2020Date on which the examining division has become responsible
27.05.2020Despatch of a communication from the examining division (Time limit: M04)
21.08.2020Reply to a communication from the examining division
19.02.2021Cancellation of oral proceeding that was planned for 23.03.2021
02.03.2021Despatch of a communication from the examining division (Time limit: M04)
05.03.2021Reply to a communication from the examining division
23.03.2021Date of oral proceedings (cancelled)
15.04.2021Communication of intention to grant the patent
15.07.2021Fee for grant paid
15.07.2021Fee for publishing/printing paid
15.07.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07867341.5  / EP2078197
EP16151995.4  / EP3029461
EP17192133.1  / EP3276349
Opposition(s)27.05.2022No opposition filed within time limit [2022/31]
Fees paidRenewal fee
06.06.2019Renewal fee patent year 03
06.06.2019Renewal fee patent year 04
06.06.2019Renewal fee patent year 05
06.06.2019Renewal fee patent year 06
06.06.2019Renewal fee patent year 07
06.06.2019Renewal fee patent year 08
06.06.2019Renewal fee patent year 09
06.06.2019Renewal fee patent year 10
06.06.2019Renewal fee patent year 11
06.06.2019Renewal fee patent year 12
14.11.2019Renewal fee patent year 13
10.11.2020Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.11.2007
AT25.08.2021
CY25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
TR25.08.2021
IE01.11.2021
LU01.11.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
[2024/29]
Former [2023/33]HU01.11.2007
AT25.08.2021
CY25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
IE01.11.2021
LU01.11.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
Former [2023/24]AT25.08.2021
CY25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
IE01.11.2021
LU01.11.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/48]AT25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
IE01.11.2021
LU01.11.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/36]AT25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
LU01.11.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/34]AT25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SK25.08.2021
LU01.11.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/33]AT25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SK25.08.2021
BG25.11.2021
GR26.11.2021
BE30.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/24]AT25.08.2021
CZ25.08.2021
EE25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SK25.08.2021
BG25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/16]AT25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
SE25.08.2021
BG25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/11]AT25.08.2021
FI25.08.2021
LT25.08.2021
LV25.08.2021
PL25.08.2021
SE25.08.2021
BG25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/09]AT25.08.2021
FI25.08.2021
LT25.08.2021
SE25.08.2021
BG25.11.2021
PT27.12.2021
Former [2022/08]AT25.08.2021
FI25.08.2021
LT25.08.2021
SE25.08.2021
BG25.11.2021
Documents cited:Search[Y]WO9503296  (ABBOTT LAB [US]) [Y] 1-12 * the whole document * * in particular: * * claims 1,23-25,27 * * example 27 * * page 15, line 22 - line 25 * * page 4, line 1 - line 30 * * page 9, line 17 - line 21 *;
 [Y]WO2005064018  (VENTANA MED SYST INC [US], et al) [Y] 1-12 * the whole document * * in particular: * * example 11 * * page 8, line 9 - page 11, line 15 *;
 [XY]  - DARMON A ET AL, "A method for measuring anion transfer across membranes of hemoglobin-free cells and vesicles by continuous monitoring of fluorescence", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 119, no. 2, doi:10.1016/0003-2697(82)90591-7, ISSN 0003-2697, (19820115), pages 313 - 321, (19820115), XP024830638 [X] 10 * abstract * * par. "Anti-NBD antibodies"; page 314 * [Y] 1-9,11,12

DOI:   http://dx.doi.org/10.1016/0003-2697(82)90591-7
 [XY]  - M. VIGUIER ET AL, "The invariant chain forms complexes with class II major histocompatibility complex molecules and antigenic peptides "in vivo".", NATIONAL ACADEMY OF SCIENCES, US, (19900901), vol. 87, no. 18, doi:10.1073/pnas.87.18.7170, ISSN 0027-8424, pages 7170 - 7174, XP055258750 [X] 10 * abstract * * page 7171, column l, paragraph 1 - paragraph 2 * * page 7171, column r, line 10 - line 37 * [Y] 1-9,11,12

DOI:   http://dx.doi.org/10.1073/pnas.87.18.7170
 [Y]  - WATKINS B E ET AL, "THE SYNTHESIS OF HAPTENIC DERIVATIVES OF AMINOIMIDAZOAZAARENE COOKED-FOOD MUTAGENS", HETEROCYCLES, JAPAN INSTITUTE OF HETEROCYCLIC CHEMISTRY, JP, (19870101), vol. 26, no. 8, doi:10.3987/R-1987-08-2069, ISSN 0385-5414, pages 2069 - 2072, XP008159115 [Y] 1-12 * page 2071, line 1 - line 5 * * Scheme 2; page 2071 *

DOI:   http://dx.doi.org/10.3987/R-1987-08-2069
 [Y]  - PUTTAIAH S ET AL, "Detection of dideoxyosone intermediates of glycation using a monoclonal antibody: Characterization of major epitope structures", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, ACADEMIC PRESS, US, vol. 446, no. 2, doi:10.1016/J.ABB.2005.12.002, ISSN 0003-9861, (20060215), pages 186 - 196, (20060215), XP024942997 [Y] 1-12 * the whole document * * in particular: * * abstract * * page 187, column r, line 7 - page 188, column r, line 18 *

DOI:   http://dx.doi.org/10.1016/j.abb.2005.12.002
by applicantUS4036945
 US4331647
 US4469797
 US4652441
 US4675189
 US4677191
 US4728721
 US4917893
 US4946778
 US5143854
 US5198537
 WO9617958
 US5585089
 US5650327
 US5654200
 US5759808
 US5800988
 US5840526
 US5874541
 US6005079
 US6015695
 US6194388
 US6207646
 US6214806
 US6218371
 US6239116
 US6296809
 US6326148
 US6339068
 US6352861
 US6406705
 US6429199
 US2003211630
 US6649138
 US6682596
 US2004052685
 US2004057958
 US6815064
 US6827901
 WO2005001889
 US2005012182
 US6943029
    - PAVLIAKOVA et al., Infect. Immun., (20000000), vol. 68, pages 2161 - 66
    - ENGELHARD, Curr. Opin. Immunol., (19940000), vol. 6, page 13
    - "New Biotinylating Reagent Utilizing Carbodiimide Function", Nucleic Acid Symposiums Series, (19950000), pages 69 - 70
    - SINGH et al., Nat. Biotechnol., (19990000), vol. 17, pages 1075 - 1081
    - SCHUMMER, Biotechniques, (19970000), vol. 23, pages 1087 - 1092
    - DEVI et al., PNAS, (19910000), vol. 88, pages 7175 - 79
    - FRANKEL et al., Mol. Immunol., (19790000), vol. 16, pages 101 - 106
    - POZSGAY et al., PNAS, (19990000), vol. 96, pages 5194 - 97
    - LEE et al., J. Immunol., (19760000), vol. 116, pages 1711 - 18
    - DINTZIS et al., PNAS, (19760000), vol. 73, pages 3671 - 75
    - FATTOM et al., Infect. Immun., (19900000), vol. 58, pages 2309 - 12
    - SZU et al., Infect. Immun., (19910000), vol. 59, pages 4555 - 61
    - SZU et al., J. Exp. Med., (19870000), vol. 166, pages 1510 - 24
    - J.C. CONNOLLYR. A. HILL, Triterpenoids, Nat. Prod. Rep., (20020000), vol. 19, pages 494 - 513
    - BAGLIN et al., A Review of Natural and Modified Beculinic, Ursolic and Echinocystic Acid Derivatives as Potential Antitumor and Anti-HIV Agents, Mini Reviews in Medicinal Chemistry, vol. 3, pages 525 - 539
    - W.N.M.C. SETZER, "Plant-Derived Triterpenoids as Potential Antineoplastic Agents", Mini Reviews in Medicinal Chemistry, (20030000), vol. 3, pages 540 - 556
    - BALTINA, "Chemical Modification of Glycyrrhizic Acid as a Route to New Bioactive Compounds for Medicine", Current Medicinal Chemistry, (20030000), vol. 10, pages 155 - 171
    - LESLIE CROMBIEDONALD WHITING, Biosynthesis in the Rotenoids Group of Natural Products: Application of Isotope Methodology, Phytochemistry, (19980000), vol. 49, pages 1479 - 1507
    - STEPHANIE DESBENESYLVIANE GIORGI-RENAULT, "Drugs that Inhibit Tubulin Polymerization: The Particuar Case of Podophyllotoxin and Analogues", Curr. Med. Chem. - Anti-Cancer Agents, (20020000), vol. 2, pages 71 - 90
    - M. GORDALIZA et al., "Podophyllotoxin: Distribution, Sources, Applications and New Cytotoxic Derivatives", Toxicon, (20040000), vol. 44, pages 441 - 459
    - PHILLIPE MERESSE et al., "Etoposide: Discovery and Medicinal Chemistry", Current Medicinal Chemistry, (20040000), vol. 11, pages 2443 - 2466
    - M. PUJOL et al., "Synthesis and Biological Activity of New Class of Dioxygenated Anticancer Agents", Curr. Med. Chem. - Anti-Cancer Agents, (20050000), vol. 5, pages 215 - 237
    - YOUNGJAE YOU, "Podophyllotoxin Derivatives: Current Synthetic Approaches for New Anticancer Agents", Current Pharmaceutical Design, (20050000), vol. 11, doi:doi:10.2174/1381612053764724, pages 1695 - 1717, XP055120074

DOI:   http://dx.doi.org/10.2174/1381612053764724
    - WU, X. et al., Nature Biotech., (20030000), vol. 21, pages 41 - 46
    - WU, X. et al., "Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots", Nature Biotechnol., (20030000), vol. 21, doi:doi:10.1038/nbt764, pages 41 - 46, XP055509491

DOI:   http://dx.doi.org/10.1038/nbt764
    - JAISWAL, J. K.MATTOUSSI, H.MAURO, J. M.SIMON, S. M., "Long-term multiple color imaging of live cells using quantum dot bioconjugates", Nature Biotechnol., (20030000), vol. 21, pages 47 - 51
    - DUBERTRET, B. et al., "In vivo imaging of quantum dots encapsulated in phospholipid micelles", Science, (20020000), vol. 298, doi:doi:10.1126/science.1077194, pages 1759 - 1762, XP002255863

DOI:   http://dx.doi.org/10.1126/science.1077194
    - RIGBY, PWDIECKMANN, MRHODES, C.BERG, P., "Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I", J. Mol. Biol., VI, (19770000), vol. 13, doi:doi:10.1016/0022-2836(77)90052-3, pages 237 - 251, XP024012125

DOI:   http://dx.doi.org/10.1016/0022-2836(77)90052-3
    - MICHAEL et al., J. Pharmacy Pharmacol., (19910000), vol. 43, pages 1 - 5
    - HARRIS, Nat Rev., (20020000), vol. 2, pages 38 - 47
    - FODOR, Science, (19910000), pages 767 - 773
    - JOHNSTON, Curr. Biol., (19980000), vol. 8, pages R171 - R174
    - HOOS et al., Am J Pathol., (20010000), vol. 158, pages 1245 - 51
    - JONES et al., Nature, (19860000), vol. 321, page 522
    - RIECHMANN et al., Nature, (19880000), vol. 332, page 323
    - VERHOEYEN et al., Science, (19880000), vol. 242, page 1534
    - CARTER et al., Proc. Natl. Acad. Sci. U.S.A., (19920000), vol. 89, page 4285
    - SANDHU, Crit. Rev. Biotech., (19920000), vol. 12, page 437
    - SINGER et al., J. Immunol., (19930000), vol. 150, page 2844
    - WHITLOW et al., Methods: a Companion to Methods in Enzymology, (19910000), vol. 2, page 97
    - PACK et al., BiolTechnology, (19930000), vol. 11, page 1271
    - NISONHOFF et al., Arch. Biochem. Biophys., (19600000), vol. 89, page 230
    - PORTER, Biochem. J., (19590000), vol. 73, page 119
    - EDELMAN et al., Methods in Enzymology, Academic Press, (19670000), vol. 1, page 422
    - BUCHNER et al., Anal. Biochem., (19920000), vol. 205, pages 263 - 270
    - PLUCKTHUN, Biotechnology, (19910000), vol. 9, page 545
    - HUSE et al., Science, (19890000), vol. 246, page 1275
    - WARD et al., Nature, (19890000), vol. 341, page 544
    - SAXENA et al., Biochemistry, (19700000), vol. 9, pages 5015 - 5021
    - BARANYMERRIFIELD, The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, vol. 2, pages 3 - 284
    - MERRIFIELD et al., J. Am. Chem. Soc., (19630000), vol. 85, pages 2149 - 2156
    - NOVELLINO et al., Cancer Immunol. Immunother, (20050000), vol. 54, no. 3, pages 187 - 207
    - CHEN et al., Cytotherapy, (20020000), vol. 4, pages 41 - 8
    - SOUTHWOOD et al., J. Immunol., (19980000), vol. 160, page 3363
    - RAMMENSEE et al., Immunogenetics, (19950000), vol. 41, page 178
    - RAMMENSEE et al., J. Curr. Opin. Immunol., (19980000), vol. 10, page 478
    - SETTEGREY, Curr. Opin. Immunol., (19920000), vol. 4, page 79
 US20050675759
 US20050739794
 US20060413415
 US20060413778
 US20070931546
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.